世界肉瘤网络关于TRK融合肉瘤诊疗的专家建议
肉瘤是间叶来源的异质性恶性肿瘤,NTRK基因融合作为组织不可知驱动因素,使TRK抑制剂成为部分肉瘤患者的个体化治疗选择。世界肉瘤网络召集两次成人肿瘤内科与病理专家会议,针对NTRK基因融合的罕见性与诊断复杂性提出实用管理建议,并给出结合疾病分期、组织学与分子亚型的诊断策略以促进常规TRK表达检测及后续NTRK基因融合检测。
要点
- NTRK基因融合是部分肉瘤的致癌驱动因素,TRK抑制剂为相应患者提供个体化治疗。
- TRK蛋白表达可用免疫组化检测,NTRK基因重排与融合转录本可用不同分子病理技术检测。
- 建议根据疾病分期、组织学与分子亚型制定诊断策略,促进常规TRK表达检测及后续NTRK融合检测。
核心结论
- 世界肉瘤网络专家针对携带NTRK基因融合的肉瘤患者管理提出实用指导。
研究设计与样本
- 世界肉瘤网络召集两次成人肿瘤内科与病理专家会议后制定该专家建议文章。
主要发现
- NTRK基因融合是部分肉瘤的组织不可知致癌驱动因素,TRK抑制剂为其个体化治疗形式。
- NTRK基因重排与融合转录本可用不同分子病理技术检测,TRK蛋白表达可用免疫组化显示。
关键数值与推荐
- 建议诊断策略考虑疾病分期、组织学与分子亚型,以促进常规TRK表达检测及后续NTRK基因融合检测。
临床怎么用
- 临床可依据疾病分期、组织学与分子亚型选择路径,先行常规TRK表达检测再行NTRK基因融合检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a subset of patients with sarcoma in the form of tropomyosin receptor kinase (TRK) inhibitors. NTRK gene rearrangements and fusion transcripts can be detected with different molecular pathology techniques, while TRK protein expression can be demonstrated with immunohistochemistry. The rarity and diagnostic complexity of NTRK gene fusions raise a number of questions and challenges for clinicians. To address these challenges, the World Sarcoma Network convened two meetings of expert adult oncologists and pathologists and subsequently developed this article to provide practical guidance on the management of patients with sarcoma harboring NTRK gene fusions. We propose a diagnostic strategy that considers disease stage and histologic and molecular subtypes to facilitate routine testing for TRK expression and subsequent testing for NTRK gene fusions.
引用
- Demetri GD, Antonescu CR, Bjerkehagen B, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020. PMID: 32891793. doi:10.1016/j.annonc.2020.08.2232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。